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ABSTRACT Immunotoxins were made using five different
murine monoclonal antibodies to the human erbB2 gene prod-
uct and LysPE40, a 40-kDa recombinant form ofPseudomonas
exotoxin (PE) lacking its cell-binding domain. All five conju-
gates were specifically cytotoxic to cancer cell lines overex-
pressing erbB2 protein. The most active conjugate was e23-
LysPE40, generated by chemical crosslinking of anti-erbB2
monoclonal antibody e23 to LysPE40. In addition, a recombi-
nant immunotoxin, e23(Fv)PE40, was constructed that consists
of the light-chain variable domain of e23 connected through a
peptide linker to its heavy-chain variable domain, which in turn
is fused to PE40. The recombinant protein was made in
Escherichia coli, purified to near homogeneity, and shown to
selectively kill cells expressing the erbB2 protooncogene. To
improve the cytotoxic activity of e23(Fv)PE40, PE40 was
replaced with a variant, PE38KDEL, in which the carboxyl end
of PE is changed from Arg-Glu-Asp-Leu-Lys to Lys-Asp-Glu-
Leu and amino acids 365-380 of PE are deleted. The
e23(Fv)PE38KDEL protein inhibits the growth of tumors
formed by the human gastric cancer cell line N87 in immuno-
deficient mice.
Clinical trials are under way in which monoclonal antibodies
are used to carry cytotoxic substances to tumor cells. Im-
munotoxins made by coupling monoclonal antibodies (mAbs)
to toxins have been found to kill cancer cells in vitro and also
to have antitumor activities in mice bearing human tumor
xenografts (1-4). Amplification and overexpression of the
erbB2 gene has been shown to occur in many human cancers,
including "30% of lung, breast, ovary, and stomach adeno-
carcinomas (5-11). In breast carcinoma, a correlation has
been observed between gene amplification and overexpres-
sion of erbB2 protein and the aggressiveness of the malig-
nancy (7, 8). In cases of gene amplification, there is a
resulting 50- to 100-fold increase in erbB2 mRNA compared
with normal cell levels (11). The overexpression of erbB2 has
been directly linked to the malignant conversion of cancer
cells (12, 13). This causative role for the erbB2 protein makes
it an excellent target for immunotoxin therapy because can-
cer cells are unlikely to be able to escape treatment by loss
of the antigen.
Pseudomonas exotoxin A (PE) and its recombinant forms
have been used to make immunotoxins either by conven-
tional chemical coupling methods or by recombinant DNA
methods (3, 4, 14-17). PE is made of three structural do-
mains. The N-terminal domain (I) is responsible for the
binding oftoxin to its receptor on the cells, the middle domain
(domain II) has a role in the translocation of toxin across the
membrane, and the C-terminal domain (III) has the ADP-
ribosylation activity (18). Recently, molecularly defined im-
munotoxins have been engineered by fusing domains II and
III of PE to the light- and heavy-chain variable regions of
specific mAbs. In the resulting single-chain immunotoxin the
cell-binding domain of PE is replaced with an antigen com-
bining site in the form of a single-chain antibody, or SC(Fv).
Here, we report the construction of several immunotoxins
using various anti-erbB2 antibodies that have been coupled to
native LysPE40, which is a recombinant form of PE devoid
of its cell-binding domain. The resulting immunotoxins were
specifically cytotoxic to cells expressing erbB2 with varying
degrees of activity. We selected one mAb, e23, to make a
single-chain chimeric immunotoxin termed e23(Fv)PE40. In
e23(Fv)PE40, the variable domain of the light chain of mAb
e23 is attached through a peptide linker to the variable
domain of the heavy chain, which in turn is fused to domains
II and III of PE. The immunotoxin was found to be specif-
ically cytotoxic to cells expressing erbB2 and was more
active than the chemical conjugate. To increase the activity
further, other derivatives of this single-chain immunotoxin
were made in which the toxin part of the molecule was
altered. One of these molecules, e23(Fv)PE38KDEL, inhib-
ited the human gastric cancer cell line N87 growing as a tumor
in immunodeficient mice.
MATERIALS AND METHODS
Antibodies and Cell Lines. el, e23, e21, e68, and e94 are
mouse mAbs against erbB2 gene product (19). The erbB2-
expressing cell lines used were BT474 (breast carcinoma),
N87 (gastric carcinoma), and SK-OV-3 (ovarian carcinoma).
A431 and KB are human epidermoid carcinomas that express
low levels of erbB2.
Construction of Chemical Conijugates. LysPE40 or PE was
coupled chemically to mAbs by a thioether linkage using
2-iminothiolane and succinimidyl-4-(N-maleimidomethyl)cy-
clohexane-1-carboxylate to derivatize the antibody and the
toxin, respectively (3). Conjugates were purified as described
(3).
Generation of a SC(Fv) from mAb e23. Poly(A)+ RNA was
extracted from hybridoma cells by oligo(dT) affinity chro-
matography (Invitrogen, San Diego). cDNA was prepared
using random hexanucleotide primer (Boehringer Mann-
heim). The immunoglobulin light- and heavy-chain clones
were isolated using PCR with the following primers: light
chain, 5'-CAC-GTC-GAC-ATT-CAG-CTG-ACC-CAC-
TCT-CCA-3' and 5'-GAT-GGA-TCC-AGT-TGG-TGC-
AGC-ATC-3'; heavy chain, 5'-C-GGA-ATT-TCA-GGT-
TCT-GCA-GIA-GTC-WGG-3' and 5'-AGC-GGA-TCC-
AGG-GGC-CAG-TGG-ATA-GAC-3' (I, deoxyinosine; W, A
Abbreviations: mAb, monoclonal antibody; PE, Pseudomonas ex-
otoxin; SC(Fv), single-chain antibody comprising heavy- and light-
chain variable regions.
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or T). The products of the PCR reaction were cloned into
plasmid pUC18. Linkage into a SC(Fv) was by PCR involving
the individual light- and heavy-chain cDNA clones and four
oligonucleotides. The light- and heavy-chain regions were
joined by a synthetic linker with amino acid sequence
GSTSGSGKSSEGKG specified by overlapping oligonucle-
otides as described. The intact SC(Fv) coding region was
inserted in frame with an ompA leader sequence under
direction of the A PL promoter. Induction ofprotein, and lysis
of bacteria, and refolding of protein were as previously
described (20). The SC(Fv) was purified as a single peak from
CM chromatography and judged to be >70o pure by SDS/
PAGE.
Plasmids. Plasmid pJB23-40 encodes e23(Fv)PE40 and con-
tains cDNA for light-chain variable region of anti-erbB2 an-
tibody e23 connected through a 42-base-pair linker to its
heavy-chain variable region, which in turn is fused to theDNA
for PE40 (see Fig. 3). The fusion gene is under the control of
a bacteriophage T7 late promoter and the plasmid also contains
phage fl origin and a terminator. Plasmid pJB23-38 encodes
the protein termed e23(Fv)PE38. In pJB23-38, codons for
amino acids 365-380 in domain II of PE40 have been deleted.
The Fv portion is the same as in pJB23-40. In pJB23-38K, the
codons for amino acids REDLK at the 3' end ofpJB23-38 have
been replaced with those coding for amino acids KDEL (21).
The protein encoded by this plasmid is termed e23(Fv)-
PE38KDEL. In pJB23-40K, the codons for amino acids
REDLK at the 3' end of pJB23-40 have been replaced with
those coding for amino acids KDEL (22). The protein encoded
by this plasmid is termed e23(Fv)PE40KDEL.
Expression and Purification of Proteins. Expression and
purification of various fusion proteins in Escherichia coli
were performed as described (21).
Characterization of Immunotoxins. Cytotoxic activities of
the chimeric toxins were determined by assaying the inhibi-
tion of protein synthesis in various target and nontarget cells
(3). Cells were plated in 24-well plates and 24 hr later washed
once with medium before addition of the toxins. Results are
described as percent of control where no toxin was added.
For competition experiments, an excess of antibody (20
,tg/ml) was added prior to the addition of the toxin.
In binding studies 1251-labeled e23 Fab was added as a
tracer with various concentrations of the competitor (16).
Protein was assayed by the Bradford method using Pierce
Coomassie blue "plus" reagent. SDS/PAGE was done by
the method of Laemmli (23).
For in vivo studies N87 tumor cells (5 x 106 per mouse)
were subcutaneously injected into the flanks ofBNX (beige,
nude, xid) mice on day 0. Starting on day 10, six intravenous
tail vein treatments (2 ,ug each) were carried out over 3 days.
Tumor growth and animal weights were monitored twice a
week. Tumor growth is reported as an average relative tumor
volume calculated as (w2 x 1)/2 (mm3), where w is the width
and I is the length of the tumor, measured with calipers.
RESULTS
Previous studies have shown that individual mAbs to a single
antigen can result in immunotoxins ofwidely variable activity
(1). To determine which available anti-erbB2 mAb resulted in
an immunotoxin of highest activity, we first used chemical
crosslinking to produce anti-erbB2 immunotoxins in which
the mAbs were coupled to LysPE40 (3, 4, 21). The antibodies
used are designated el, e21, e23, e68, and e94 (19). The
activity ofthe immunotoxins was assessed by measuring their
ability to inhibit protein synthesis in target and nontarget
cells. BT474, N87, and SK-OV-3 are cell lines that overex-
press erbB2, whereas A431 and KB do not. All the conjugates
were active on BT474 cells, with e23-LysPE40 being the most
active. The same general pattern of activity was observed on
Table 1. Activity of anti-erbB2-PE40 conjugates on various
human cell lines
ID50, ng/ml
Toxin BT474 N87 SK-OV-3 A431 KB
e23-LysPE40 18 37 180 700 2000
e21-LysPE40 47 38 200 >2000 >2000
el-LysPE40 36 64 500 ND ND
e68-LysPE40 180 130 >1000 2000 2000
e94-LysPE40 42 100 600 >2000 >2000
LysPE40 160 ND >2000 650 >2000
ID"0 values are the concentrations of protein required to inhibit
protein synthesis by 50%. ND, not done.
BT474 and N87 cells, but SK-OV-3 cells were less sensitive
to these conjugates (Table 1). All of these immunotoxins had
little or no toxicity for A431 and KB cells, indicating their
specificity for erbB2. Specificity was also demonstrated by
showing that excess unconjugated antibodies prevented the
inhibition of protein synthesis by the respective immunotox-
ins (data not shown). Since e23 produced the most active
conjugate, it was used for further studies.
To compare the binding activity of e23-LysPE40 with that
of the native antibody, competition binding analyses were
performed on mouse NIH 3T3 cells engineered to express
high levels of human erbB2 protein (12). In these studies we
determined the abilities of the two immunotoxins to compete
for the binding of 1251-labeled e23 to transfected NIH 3T3 cells
overexpressing human erbB2 protein. e23-LysPE40 and
e23-PE were found to compete for binding to the erbB2
antigen very efficiently, with binding affinity slightly lower
than that of the native antibody (data not shown).
ATGGACCTGCAGCTGACCCAGTCTCCAGCAATCCTGTCTGCATCTCCAGG
MetAspLeuGlnLeuThrGlnSerProAlaIleLeuSerAlaSerProGly
GGAGAAGGTCACAATGACTTGCAGGGCCACCCCAAGTGTAAGTTACATGC
GluLysValThrMetThrCysArgAlaThrProSerValSerTyrMetHis
ACTGGTATCAGCAGAAGCCAGGATCCTCCCCCAAACCTTGGATTTATACC
TrpTyrGlnGlnLysProGlySerSerProLysProTrpIleTyrThr
ACATCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCGGTGGGTC
ThrSerAsnLeuAlaSerGlyValProAlaArgPheSerGlyGlyGlySer
TGGGACCTCTTACTCTCTCACAGTCAGCAGAGTGGAGGCTGAAGATGCTG
GlyThrSerTyrSerLeuThrValSerArgValGluAlaGluAspAlaAla
CCACTTATTACTGCCAGCAGTGGAGTCGTAGCCCACCCACGTTCGGAGGG
ThrTyrTyrCysGlnGlnTrpSerArgSerProProThrPheGlyGly
GGGTCCAAGCTGGAAATAAAAGGTTCTACCTCTGGTTCTGGTAAATCTTC
GlySerLysLeuGluIleLysQlySerThr8erGly8erGlyLys8erSer
TGAAGGTAAAGGTGTGCAGCTGCAGGAGTCAGGACCTGAGGTGGTGAAGC
GluGlyLyuGlyValGlnLeuGlnGluSerGlyProGluValValLysPro
CTGGAGGTTCAATGAAGATATCCTGCAAGACTTCTGGTTACTCATTCACT
GlyGlySerMetLysIleSerCysLysThrSerGlyTyrSerPheThr
GGCCACACCATGAACTGGGTGAAGCAGAGCCATGGAAAGAACCTTGAGTG
GlyHisThrMetAsnTrpValLysGlnSerHisGlyLysAsnLeuGluTrp
GATTGGACTTATTAATCCTTACAATGGTGATACTAACTACAACCAGAAGT
IleGlyLeuIleAsnProTyrAsnGlyAspThrAsnTyrAsnGlnLysPhe
TCAAGGGCAAGGCCACATTTACTGTAGACAAGTCGTCCAGCACAGCCTAC
LysGlyLysAlaThrPheThrValAspLysSerSerSerThrAlaTyr
ATGGAGCTCCTCAGTCTGACATCTGAGGACTCTGCAGTCTATTACTGTGC
MetGluLeuLeuSerLeuThrSerGluAspSerAlaValTyrTyrCysAla
AAGGAGGGTTACGGACTGGTACTTCGATGTCTGGGGCGCAGGGACCACGG
ArgArgValThrAspTrpTyrPheAspValTrpGlyAlaGlyThrThrVal
TCACCGTCTCC
ThrValSer
FIG. 1. Nucleotide and amino acid sequence of the SC(Fv) for
e23. The linker joining the light-chain and heavy-chain variable
regions is shown in bold.
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FIG. 2. Cytotoxicity of e23(Fv)PE40 on BT474 cells as shown by
inhibition of protein synthesis. Results are shown as percentage of
control cells to which no toxin was added. e, e23(Fv)PE40 alone; o,
e23(Fv)PE40 plus native e23 (20 Jig/ml); A, e23-LysPE40.
Construction of Single-Chain Immunotoxin with Anti-erbB2
Antibody e23. Single-chain immunotoxins made by the fusion
of the antigen-binding region (Fv) and PE40 can retain the
binding affinity of the native antibody and are often more
active than the respective chemical conjugates (15, 16). For
this reason, we selected antibody e23 for construction of a
first-generation recombinant immunotoxin. First, an intact
SC(Fv) for e23(Fv) coding region was generated essentially
as previously described. The sequence of the single-chain
protein is shown in (Fig. 1). To verify the binding activity of
the purified e23(Fv) protein we conducted competition bind-
ing using 1251-labeled e23 Fab (see Fig. 5). The overall
structure of our first recombinant immunotoxin is the amino-
terminal e23 SC(Fv) domain joined to the translocation (II)
and ADP-ribosylating (III) domains of PE. The assembled
gene is under control of a bacteriophage T7 promoter. The
resulting plasmid, pJB23-40, expresses the variable region of
the light chain of e23, a 14-amino acid linker peptide, the
variable region of the heavy chain of e23, and amino acids
253-613 ofPE. The chimeric protein was expressed in E. coli
and purified. The resulting protein was >70% pure as judged
by SDS/PAGE (data not shown).
Cytotoxicity of e23(Fv)PE40. e23(Fv)PE40 was tested on
BT474 breast cancer cells and was found to inhibit protein
synthesis in a dose-dependent manner with an IDso of 1.5
ng/ml (Fig. 2, Table 2). The cytotoxic activity was blocked by
competition with excess native e23, demonstrating the spec-
ificity of e23(Fv)PE40 for erbB2-containing cells (Fig. 2).
Another anti-erbB2 monoclonal antibody, e21, which binds to
a different site, had no effect on the toxicity of e23(Fv)PE40
(data not shown). In the same experiment, e23-LysPE4O, the
chemical conjugate, had an ID50 of 12 ng/ml (Fig. 2, Table 2).
The activity of e23(Fv)PE40 was assayed on several cell lines
expressing erbB2 and compared with that of the chemical
Table 2. Comparison of activity of e23(Fv)PE40 and chemical
conjugates on various human cell lines
IDso ng/ml (pM) Relative
Cells e23(Fv)PE40 e23-LysPE40 activity*
BT474 1.5 (23) 12 (63) 0.37
N87 3.5 (54) 24 (126) 0.43
SK-OV-3 22.0 (338) 180 (947) 0.36
SK-Br-3 32.0 (492) 180 (947) 0.52
A431 170.0 (2615) >500 (>2631) NC
*Ratio of ID50 (pM) of e23(Fv)PE40 to ID50 of e23-LysPE40 on the
same cell line. NC, not calculated.
pJB23-40 VL L I VH 11 I Ibl III FREDLK
pJB23-38 VL L VH 11 III REDLK
pJB23-38K VL L VH II III KDEL
pJB23-40K VL I L I VH I 11 I ll1 KDEL
FIG. 3. Various e23(Fv)PE40 derivatives. VH, variable region of
heavy chain; VL, variable region of light chain; L, linker; II, domain
II of PE; lb, domain lb of PE; III, domain III of PE. Carboxyl-
terminal amino acid sequences are shown in single-letter code.
conjugate, e23-LysPE40 (Table 2). On all four target cells,
e23(Fv)PE40 was active and the ID50 values on a molar basis
were 2- to 3-fold lower than those of e23-LysPE40. Both
molecules had very little activity on KB cells, showing their
specificity for erbB2-expressing cells.
Derivatives of e23(Fv)PE40. The carboxyl terminus of PE
ends in the amino acids REDLK. Replacing REDLK with
KDEL results in molecules that have 3- to 10-fold higher
cytotoxic activities (21). Also, deleting part of domain lb of
PE-i.e., amino acids 365-380, thereby deleting a disulfide
bond-does not result in any loss of activity of several fusion
proteins including TGFa-PE40, anti-Tac(Fv)-PE40, and
B3(Fv)PE40 (17, 24). Since mixed disulfide bonds can form
during the renaturation of recombinant proteins, we thought
it would be helpful to delete this region. To explore the
possibility of making a much more active derivative of
e23(Fv)PE40, we made three new constructions: (i)
e23(Fv)PE40KDEL, where the carboxyl terminus REDLK is
replaced by KDEL in e23(Fv)PE40; (ii) e23(Fv)PE38, in
which amino acids 365-380 have been deleted from
e23(Fv)PE40 but the carboxyl terminus is still REDLK; and
(iii) e23(Fv)PE38KDEL, where REDLK is replaced by
KDEL in e23(Fv)PE38. These derivatives are diagramed in
Fig. 3. The chimeric proteins were also purified to >70%
purity and tested for cytotoxic activity on target cells. As
shown in Fig. 4, all of the new derivatives inhibited the
protein synthesis of BT474 cells in a dose-dependent manner,
with e23(Fv)PE38KDEL being the most active. Table 3
summarizes the ID50 values of the e23(Fv)P40 derivatives on
various cell lines. On all three target cell lines, e23(Fv)-
PE38KDEL, was found to be the most active. e23(Fv)-
PE38KDEL was 6- to 10-fold more active than e23(Fv)PE40
(Table 3). None of the proteins had any cytotoxicity on KB
cells, a cell line that does not overexpress erbB2. In the
presence of excess e23, the cytotoxic activity of all deriva-
tives was abolished (data not shown). The binding activity of
e23(Fv)PE38KDEL was monitored in a competition bind-
120
- e23(Fv)40
- 100 -0- e23(Fv)38K
O r <-- e23(Fv)40KD-0- e23(Fv)38
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FIG. 4. Comparative cytotoxic activities of various e23(Fv)PE40
derivatives on BT474 cells. e, e23(Fv)PE40; o, e23(Fv)PE38KDEL;
*, e23(Fv)PE40KDEL; o, e23(Fv)PE38.
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Table 3. Activity of e23(Fv)PE40 and derivatives on various
human cell lines
IDO (ng/ml)
Protein BT474 N87 SK-OV-3 KB
e23(Fv)PE40 3 8 80 >500
e23(Fv)PE40KDEL 1.6 3.8 22 >500
e23(Fv)PE38 3.6 3.7 62 >500
e23(Fv)PE38KDEL 0.18 1.2 5 >500
ing assay. As shown in Fig. 5, e23(Fv)PE38KDEL was able
to compete with homologous e23 Fab for binding, but a
higher concentration was required than for e23 Fv. This
result is consistent with either a lower overall affinity of
e23(Fv)PE38KDEL or the purified protein being a mixture of
active and inactive species. Current purification methods for
e23(Fv)PE38KDEL do not allow us to separate forms on the
basis of binding activity. To verify the binding activity of the
e23 Fv, we conducted a similar competition binding assay
and found that e23 Fv binds with slightly lower affinity than
intact antibody and monomeric Fab produced from e23 (Fig.
5).
Growth Inhibition of Human Tumors in a Nude Mouse
Model. The selective toxicity of the e23(Fv)PE38KDEL to
cells overexpressing erbB2 encouraged us to attempt to treat
human tumor cells growing in nude mice. The human gastric
cancer cell line N87 has been shown to overexpress erbB2
protein at high levels as a result of gene amplification, and
N87 cells grow well as a subcutaneous tumor in immuno-
compromised mice (19). Injections of 5 x 106 cells on day 0
were followed by six intravenous treatments over 3 days,
starting on day 10. Immunotoxin treatment inhibited growth
of established tumors (Fig. 6). No animal deaths were ob-
served at doses of 2 ,ug. Equivalent amounts of either e23
Fab, e23 SC(Fv) (data not shown), or LysPE38KDEL had no
effect on tumor growth. Nonspecific toxicity was assayed by
monitoring the animal weight; no weight loss was observed at
doses of 2 gg.
DISCUSSION
We examined the activity ofimmunoconjugates of anti-erbB2
mAbs. All immunotoxins were selectively toxic to cells
overexpressing erbB2. Most active were conjugates of mAb
e23, which was thus selected for constructing a recombinant
5-
co,
0
x
E0.
4.
3.
2-
I . -
0.1 1 10
Competitor, nM
10. .1
100 1 000
E
E
E 1000 i
0
E THERAPY ENDS
:3
4-500-
C
0 10 20 30
Days after therapy started
FIG. 6. Therapy of tumors formed in mice by human gastric
cancer cell line N87. Tumors were established by injection of 5 x 106
N87 cells subcutaneously on the backs of BNX mice. Therapy was
initiated 7 days following injection of cells. Treatments were twice
daily injections in the tail vein with 2 ug of e23(Fv)PE38KDEL (*),
LysPE38KDEL (o), or e23 Fab (A) or with phosphate-buffered saline
(o). Measurements were conducted externally with calipers.
immunotoxin. This recombinant immunotoxin contains a
SC(Fv) linked to PE40. As observed previously (17), the
recombinant immunotoxin was 2- to 3-fold more active than
the analogous chemical conjugate, and, we achieved an
additional 6- to 10-fold increase in cytotoxic activity by
changing the carboxyl terminus of PE from REDLK to
KDEL and by deleting 15 amino acids from domain II of PE.
This latter modification is likely to aid in formation of
properly folded molecules. Our results indicate that
e23(Fv)PE38KDEL is a potent cytotoxic molecule capable of
binding specifically to the erbB2 protein. Improved refolding
of e23(Fv)PE38KDEL or increasing its binding affinity could
significantly improve the effectiveness of this molecule.
The potential clinical application of an immunotoxin such
as e23(Fv)PE38KDEL is based on the overexpression of the
185-kDa erbB2 glycoprotein (gp185 erbB2) in about 30%o of
adenocarcinomas of the breast, stomach, lung, and ovary.
Since gp185 erbB2 is expressed on normal cells, therapeutic
efficacy will probably require administration of doses in a
range sufficient to kill cells that overexpress erbB2, but with
limited toxicity to normal cells. Direct evidence for the
potential of e23(Fv)PE38KDEL is provided by our results
showing inhibition of tumor growth in nude mice. The N87
cells used in these experiments overexpress gp185 erbB2 at
high levels. At sublethal doses ofe23(Fv)PE38KDEL, tumor
growth was significantly reduced. It should be noted that a
potentially important form of toxicity was not apparent in this
experiment, as we do not expect the e23(Fv)PE38KDEL to
bind to murine gp185 erbB2 (neu) gene product. Such toxicity
will need to be addressed in animal toxicity experiments
where the e23(Fv)PE38KDEL binds to endogenous erbB2
proteins. Our results do suggest that e23(Fv)PE38KDEL may
have application in treatment of certain highly malignant
tumors, such as adenocarcinoma of the stomach, lung,
breast, and ovary.
We thank M. Gallo, E. Lovelace, and T. Clayton for their valuable
assistance.
FIG. 5. Binding ofSC(Fv) and immunotoxin to erbB2. The ability
of purified e23 Fv (o) and e23(Fv)PE38KDEL (e) to inhibit the
binding of 1125-labeled e23 Fab was measured using cells overex-
pressing erbB2 (N87) as the binding target. Also shown are e23 Fab
(o) and intact antibody e23 (A).
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